EICHORPublic-registry site landscape for NCT05172596, “PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma”, a Multiple Myeloma study sponsored by Novartis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05172596 (registry record) |
| Study title | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma |
| Official title | A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma. |
| Sponsor | Novartis Pharmaceuticals |
| Condition(s) | Multiple Myeloma |
| Phase | PHASE2 |
| Listed sites | 36 |
| Site countries | United States, Australia, Brazil, Canada, France, Germany, Greece, Israel, Italy, Japan, Saudi Arabia, Singapore |
Patient-friendly overview of this study: eichor.com/study/NCT05172596.
Eichor generates a preliminary site-risk snapshot for NCT05172596 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Multiple Myeloma trials
More from Novartis Pharmaceuticals
← Eichor home · All tracked trials · Multiple Myeloma studies · Weekly briefs
